Expert Interview
Discussing Gubra's Phase 1 trial data for GUBamy, a long-acting amylin analogue for the management of weight loss.
Ticker(s): GUBRA- Completed medical school at the University of Minnesota.
- Practicing in endocrinology for over 20 years.
- Manages around 400 patients annually for weight loss and obesity.
Roughly how many patients do you manage weight loss?
Added By: nikki_adminOn a scale from 1-10 (10 being extremely excited), how excited are you for the Phase 1 trial data for GUBamy?
Added By: nikki_adminCan you discuss your professional background and details about your clinical practice, including the volume of patients you manage for obesity annually?
Added By: slingshot_insightsHow do GLP-1 agonists currently play a role in weight loss management, how is this evolving, and what unmet needs or limitations of current products should new therapies address?
Added By: slingshot_insightsWhat are your thoughts on amylin as a potential target for weight loss, and do you see combination therapies, such as amylin analogs with GLP-1s, as the future of obesity treatment?
Added By: slingshot_insightsHow do you interpret the weight loss data and tolerability profile from GUBamy’s Phase 1 trial, including the impact of side effects like nausea on its potential as a standalone or combination therapy?
Added By: slingshot_insightsWhat developments in obesity treatment, such as muscle-sparing agents or oral drugs, are most promising, and what are the economic and societal implications of more effective treatments?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
